Director, Clinical Operations
Fiona Patterson has more than fifteen years of experience managing and conducting clinical trials. She joined Advantagene from Infinity Pharmaceuticals where she spearheaded the duvelisib Phase III study in Chronic Lymphocytic Leukemia. Prior to working at Infinity, Ms. Patterson had a senior clinical operations role at Avedro running the Ophthalmic cross-linking trials. She joined Avedro from Pfizer (previously Wyeth) where she led key clinical trials, including the registration trial for BOSULIF® (bosutinib) in Chronic Myeloid Leukemia, resulting in NDA and MAA submissions. Prior to joining Wyeth, Ms. Patterson worked at Bristol Myers Squibb on the CARDIOLITE® (technetium Tc99m sestamibi) program. Ms. Patterson joined BMS from Millennium Pharmaceuticals (now Takeda Oncology), where she started her clinical operations career in 2001 working on Millennium’s clinical trials team in support of the NDA and sNDAs for VELCADE® (bortezomib) in Multiple Myeloma, Mantle Cell Lymphoma, and other oncologic indications. Prior to 2001, she led the Sequencing Production Group at Millennium. Ms. Patterson started her research industry career at PBI-C in the UK (now Monsanto).
|Board of Directors|